drug delivery

Functional Characteristics of C-Terminal Lysine to Cysteine Mutant Form of CTLA-4Ig.

Published April 7, 2013

Functional Characteristics of C-terminal Lysine to Cysteine Mutant Form of CTLA-4Ig.

Immune Netw. 2013 Feb; 13(1): 16-24
Kim B, Shin JS, Park CG

CTLA-4Ig is regarded as an inhibitory agent of the T cell proliferation via blocking the costimulatory… Continue reading →

[The Clinical Efficacy of a Succinate-Containing Infusion Drug During Pharmacotherapy for Hepatic Lesions of Varying Genesis: Results of Meta-Analysis].

Published March 29, 2013

[The clinical efficacy of a succinate-containing infusion drug during pharmacotherapy for hepatic lesions of varying genesis: results of meta-analysis].

Ter Arkh. 2013; 85(1): 56-61

To pool the published results of trials of the new infusion hepatoprotector remaxol for the… Continue reading →

Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice.

Published March 28, 2013

Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.

ISRN Pharmacol. 2013; 2013: 641089
Lam YW

The mapping of the human genome and subsequent advancements in genetic technology had provided clinicians and scientists an understanding of… Continue reading →

Inhaled Loxapine: A New Treatment for Agitation in Schizophrenia or Bipolar Disorder.

Published March 26, 2013

Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder.

Drugs Today (Barc). 2013 Mar; 49(3): 195-201
Owen RT

The treatment of acute agitation in psychiatric patients has traditionally involved the use of oral or intramuscular benzodiazepines,… Continue reading →

Ex Vivo ?CT Analysis of Bleomycin-Induced Lung Fibrosis for Pre-Clinical Drug Evaluation.

Published March 24, 2013

Ex vivo ?CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation.

Eur Respir J. 2013 Mar 21;
Scotton CJ, Hayes B, Alexander R, Datta A, Forty EJ, Mercer PF, Blanchard A, Chambers RC

Research into the pathogenesis underlying… Continue reading →

Drug Costs in Prediabetes and Undetected Diabetes Compared With Diagnosed Diabetes and Normal Glucose Tolerance: Results From the Population-Based KORA Survey in Germany.

Published March 24, 2013

Drug Costs in Prediabetes and Undetected Diabetes Compared With Diagnosed Diabetes and Normal Glucose Tolerance: Results From the Population-Based KORA Survey in Germany.

Diabetes Care. 2013 Apr; 36(4): e53-4
Icks A, Claessen H, Strassburger K, Tepel M, Waldeyer R,… Continue reading →

Analysis of Novel Melphalan Hydrolysis Products Formed Under Isolated Lung Perfusion Conditions Using Liquid Chromatography/tandem Mass Spectrometry.

Published March 16, 2013

Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry.

Rapid Commun Mass Spectrom. 2013 Apr 15; 27(7): 835-841
Boschmans J, de Bruijn E, Van Schil P, Lemière F

RATIONALE: Melphalan is a widely used cytotoxic agent in cancer treatments. This phenylalanine analog has been shown an effective drug in the treatment of breast cancer, multiple myeloma and melanoma of the extremities. A good knowledge of the drug’s degradation and metabolism are crucial for understanding its activity during cancer treatments. METHODS: The formation of hydrolysis products of melphalan is studied using ultra-performance liquid chromatography (UPLC) tandem mass spectrometry (MS/MS). Aqueous melphalan solutions were incubated at elevated temperatures and analyzed by UPLC/MS/MS. Two previously described hydrolysis products, mono- and dihydroxymelphalan (MOH and DOH), were formed in vitro and could be characterized during MS/MS and high-resolution experiments. RESULTS: Novel compounds with m/z values >500?Da were discovered.… Continue reading →

Efficient Isolation of Carbonyl-Reducing Enzymes Using Affinity Approach With Anticancer Drug Oracin as a Specific Ligand.

Published March 16, 2013

Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand.

J Sep Sci. 2013 Jan 24;
Skarydová L, Andrýs R, Holubová L, Stambergová H, K?avová J, Wsól V, Bílková Z

Carbonyl-reducing enzymes are… Continue reading →

Melatonin and Its Agonists in Pain Modulation and Its Clinical Application.

Published March 13, 2013

Melatonin and its agonists in pain modulation and its clinical application.

Arch Ital Biol. 2012 Dec; 150(4): 274-92
Srinivasan V, Zakaria R, Jeet Singh H, Acuna-Castroviejo D

Melatonin, the hormone of darkness has many physiological functions in the body… Continue reading →

Generation and Validation of a Zebrafish Model of EAST (Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy) Syndrome.

Published March 9, 2013

Generation and validation of a zebrafish model of EAST (Epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome.

Dis Model Mech. 2013 Feb 14;
Mahmood F, Mozere M, Zdebik AA, Stanescu HC, Tobin J, Beales PL, Kleta R, Bockenhauer D, Russell… Continue reading →